Status:
RECRUITING
Study of Dextromethorphan in OCD and Related Disorders
Lead Sponsor:
Stanford University
Collaborating Sponsors:
Avy L. & Roberta L. Miller Foundation
Conditions:
Obsessive-Compulsive Disorder
Illness Anxiety Disorder
Eligibility:
All Genders
18-65 years
Phase:
PHASE2
Brief Summary
The purpose of the study is to assess the tolerability and efficacy of dextromethorphan in combination with fluoxetine for symptom relief in OCD and related disorders.
Detailed Description
Obsessive compulsive disorder (OCD) and the related disorders body dysmorphic disorder (BDD), somatic symptom disorder (SSD) and illness anxiety disorder (IAD) are psychiatric conditions characterized...
Eligibility Criteria
Inclusion
- Diagnosis of obsessive-compulsive disorder (OCD), body dysmorphic disorder (BDD), illness anxiety disorder (IAD) or somatic symptom disorder (SSD)
- Living within California
- Capacity to provide informed consent
Exclusion
- Current bipolar disorder or psychotic disorder
- Active moderate or severe substance use disorder, lifetime severe substance use disorder
- Pregnant or nursing women
- Use of prescribed psychotropic medications other than fluoxetine for 2 weeks prior to study start
- Having commenced OCD-targeted exposure and response-prevention (ExRP) psychotherapy within 2 months of study start
Key Trial Info
Start Date :
January 20 2022
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2026
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT04899687
Start Date
January 20 2022
End Date
December 1 2026
Last Update
August 27 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Stanford University
Stanford, California, United States, 94304